Companies · ABBV
AbbVie
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 3, 2026
AbbVie Q3 2026: Skyrizi and Rinvoq sustain ~24% growth each, Apogee acquisition closes at $10.6B, and a federal court vacates Botox's IRA Medicare price selection.
AbbVie delivered $17.4 billion in Q3 2026 net revenues, up 10.3% year-over-year, driven by Skyrizi ($5.8B, +23%) and Rinvoq ($2.7B, +24%) fully offsetting Humira's accelerating biosimilar erosion (-31% in Q3). The $10.6 billion acquisition of Apogee Therapeutics closed in Q3, adding $9.1 billion in IPR&D — principally zumilokibart — and expanding AbbVie's immunology pipeline into atopic dermatitis. A U.S. District Court ruling on October 29, 2026 vacated CMS's selection of Botox for the Medicare Drug Price Negotiation Program, removing a near-term pricing overhang on a key aesthetics asset pending any government appeal.
Tone: bullishRevenue
$61.2B
ABBV 10-K · FY 2025
Employees
57,000
Revenue growth YoY
+9%
Founded
2012
Profile
ABBV 10-K Item 1 · Feb 20, 2026AbbVie is a global, research-based biopharmaceutical company with leadership positions in immunology, neuroscience, oncology and aesthetics. The company develops and commercializes advanced therapies for complex and serious diseases, led by immunology blockbusters Skyrizi and Rinvoq. AbbVie operates as a single global business segment.
Read filing description ↓ Collapse description ↑
AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories of 100% of the outstanding common stock of AbbVie to Abbott's shareholders. AbbVie's portfolio includes immunology products such as Skyrizi (risankizumab), Rinvoq (upadacitinib) and Humira (adalimumab); neuroscience products including Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev and Duodopa; oncology products such as Imbruvica, Venclexta, Elahere, Epkinly and Emrelis; and aesthetics products including Botox Cosmetic, Juvederm Collection and others. AbbVie also markets eye care products and other therapies including Mavyret, Creon and Linzess. The company markets and sells its products worldwide through wholesalers, distributors, specialty pharmacies and government agencies, and directs primary marketing efforts toward physicians and other health care providers. AbbVie's pipeline currently includes approximately 90 compounds, devices or indications in development.
Primary products
- Skyrizi
- Rinvoq
- Humira
- Vraylar
- Botox Therapeutic
- Ubrelvy
Business segments
End markets
Geographies
Named customers
In 2025, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States. No individual wholesaler accounted for greater than 43% of AbbVie's 2025 gross revenues in the United States.
Named competitors
“AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Worldwide net revenues increased by 9% on a reported and on a constant currency basis in 2025.
The rest of ABBV is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.